Mirum Pharmaceuticals Inc (MIRM) - מקדם חוב לטווח ארוך להון

Mirum Pharmaceuticals (MIRM) maintains pricing power by developing unique molecules for the therapy of critical liver pathologies. The company's products have become a steady cash generator, as reflected in the price chart with the indicator 0.00. The business generates revenue through the supply of specialized treatments for adults and children with rare diagnoses, with treatment costs covered by insurance organizations and government funds.

To filter debt risks for Mirum Pharmaceuticals (MIRM), it is critical to assess the stability of the financing structure via the ratio of liabilities with a maturity of over one year to equity. The current value of 0.00 regarding long-term loans to equity reflects the balance between borrowed capital and the asset base, which, for a pediatric biotech startup, determines the ability to sustain unique developments without threatening liquidity.